NDLI: Novel oral anticoagulants in development: Dabigatran, Rivaroxaban, and Apixaban.

Content Provider	World Health Organization (WHO)-Global Index Medicus
Author	Sattari, Maryam Lowenthal, David T.
Spatial Coverage	United States
Description	Country affiliation: United States Author Affiliation: Sattari M ( Department of Internal Medicine, University of Florida, College of Medicine, Gainesville, FL, USA. maryam.sattari@medicine.ufl.edu)
Abstract	Venous thromboembolic disease, including deep vein thrombosis and pulmonary embolism, is a cause of significant mortality and morbidity. For several decades, anticoagulant options for the treatment and prevention of thrombosis have been limited mainly to agents such as unfractionated heparin and oral vitamin K antagonists, such as warfarin. Although these therapies have proven benefits, they also have important limitations that result in their underuse in routine clinical practice. A variety of novel anticoagulants with improved pharmacologic and clinical profiles are in development, offering benefits over traditional therapies. Specifically, progress has been made in the development of small molecule factor Xa inhibitors and thrombin inhibitors. With their potentially consistent and predictable clinical profile, oral formulation, and decreased need for coagulation monitoring, these new agents will likely increase the use and duration of anticoagulation treatment in thromboembolic disorders and reduce the burden associated with long-term management.
File Format	HTM / HTML
ISSN	10752765
Issue Number	4
Volume Number	18
e-ISSN	15363686
Journal	American Journal of Therapeutics
Language	English
Publisher	Lippincott Williams & Wilkins
Publisher Date	2011-07-01
Publisher Place	United States
Access Restriction	One Nation One Subscription (ONOS)
Subject Keyword	Discipline Pharmacology Anticoagulants Therapeutic Use Benzimidazoles Morpholines Pulmonary Embolism Drug Therapy Pyrazoles Pyridines Pyridones Thiophenes Venous Thrombosis Administration, Oral Azetidines Benzylamines Dabigatran Drug Approval Humans Rivaroxaban United States Journal Article Review
Content Type	Text
Resource Type	Article
Subject	Pharmacology Pharmacology (medical)

Sl.	Authority	Responsibilities	Communication Details
1	Ministry of Education (GoI), Department of Higher Education	Sanctioning Authority	https://www.education.gov.in/ict-initiatives
2	Indian Institute of Technology Kharagpur	Host Institute of the Project: The host institute of the project is responsible for providing infrastructure support and hosting the project	https://www.iitkgp.ac.in
3	National Digital Library of India Office, Indian Institute of Technology Kharagpur	The administrative and infrastructural headquarters of the project	Dr. B. Sutradhar bsutra@ndl.gov.in
4	Project PI / Joint PI	Principal Investigator and Joint Principal Investigators of the project	Dr. B. Sutradhar bsutra@ndl.gov.in Prof. Saswat Chakrabarti will be added soon
5	Website/Portal (Helpdesk)	Queries regarding NDLI and its services	support@ndl.gov.in
6	Contents and Copyright Issues	Queries related to content curation and copyright issues	content@ndl.gov.in
7	National Digital Library of India Club (NDLI Club)	Queries related to NDLI Club formation, support, user awareness program, seminar/symposium, collaboration, social media, promotion, and outreach	clubsupport@ndl.gov.in
8	Digital Preservation Centre (DPC)	Assistance with digitizing and archiving copyright-free printed books	dpc@ndl.gov.in
9	IDR Setup or Support	Queries related to establishment and support of Institutional Digital Repository (IDR) and IDR workshops	idr@ndl.gov.in

New oral anticoagulants--a review.

Novel oral anticoagulants: a review of new agents.

New oral anticoagulants: their role and future.

The promise of novel direct oral anticoagulants.

Novel oral anticoagulants: a review of the literature and considerations in special clinical situations.

New oral anticoagulants for the treatment of venous thromboembolism.

Új antikoagulánsok a vénás thromboembolia megelozésében és kezelésében.

New oral anticoagulants: an emergency department overview.

New antithrombotic drugs and European approval processes.

Novel oral anticoagulants in development: Dabigatran, Rivaroxaban, and Apixaban.

Similar Documents

New oral anticoagulants--a review.

Novel oral anticoagulants: a review of new agents.

New oral anticoagulants: their role and future.

The promise of novel direct oral anticoagulants.

Novel oral anticoagulants: a review of the literature and considerations in special clinical situations.

New oral anticoagulants for the treatment of venous thromboembolism.

Új antikoagulánsok a vénás thromboembolia megelozésében és kezelésében.

New oral anticoagulants: an emergency department overview.

New antithrombotic drugs and European approval processes.

Novel oral anticoagulants in development: Dabigatran, Rivaroxaban, and Apixaban.